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Introduction 
Ankylosing spondylitis (AS) is a chronic systemic inflam-
matory disorder that usually begins at the age of approximate-
ly 26 years, presents more often in men than women, and 
mainly affects the axial skeleton.1) Among the well known ex-
tra-articular involvements in AS, cardiac involvements which 
include aortitis, aortic insufficiency, conduction disturbance, 
and myocardial involvement are found in some patients.2-5) 
The most prevalent manifestations are aortic regurgitation 
and conduction defects, and these are generally limited to the 
aortic root area.3-7) Although recent therapy for AS has ad-
vanced significantly, the prevalence and clinical characteristics 
of subclinical cardiac involvement in early AS remain unclear. 
The object of this study was to determine the early cardiac 
valvular changes in young male AS patients using transesoph-
ageal echocardiography (TEE), which can provide closer views 
of the aortic valve, root and subvalvular structure when com-
pared to transthoracic echocardiography (TTE).8)9)  
Methods
Study population  
Consecutive AS patients who had been managed at our in-
stitution between January 2007 and December 2008 were en-
rolled in this study. All patients were men and fulfilled the 
modified New York diagnostic criteria for AS10) and did not 
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have any history or clinical symptoms of cardiac disease. A to-
tal of 70 AS patients on treatment were divided into group I 
(< 10 years) and group II (≥ 10 years) depending on their dis-
ease duration after the first diagnosis. Twenty-five healthy vol-
unteers were selected as control subjects and were age-matched 
to group I. No female AS patient agreed to the study, and were 
consequently not enrolled. Patients were excluded if they were 
older than fifty because of possible degenerative valve dis-
ease11)12) and other potential combined rheumatologic diseases. 
This study was approved by the ethics committee of our institu-
tional review board and all subjects gave informed consent. 
Rheumatologic evaluation
The clinical evaluation included structured interview, rou-
tine blood test, and conventional X-ray. Interview included 
age at onset of first symptoms and diagnosis. In addition, medi-
cal information concerning low back pain and spinal stiffness 
(duration, severity), history of anterior uveitis, hip joint pain, 
and number of inflamed peripheral joints was obtained. We 
also assessed medical records for other missed history or events, 
as well as history of anti-tumor necrosis factor therapy (etaner-
cept). Routine blood tests were performed, and patients were 
screened for human leukocyte antigen B27, C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), and immuno-
globulin A (Ig A) for disease activity or inflammatory mark-
ers.1)13) Spinal joint and hip (sacroiliac joint) involvement was 
assessed by conventional radiology, whereas disease activity 
and functional ability were assessed by the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI).14)15) 
Echocardiography and electrocardiography
All patients underwent TEE uneventfully after TTE using 
the iE33 machine (Philips Medical Systems, Eindhoven, 
Netherlands) with a high resolution TEE probe (S7-2 Omni) 
and TTE probe (S5-1), conducted by an experienced cardiolo-
gist blinded to the clinical data. Blood pressure (BP) was mea-
sured by a sphygmomanometer while the subject was in a su-
pine position, before and after performing TEE. 
To evaluate cardiac structure (left atrial size, left ventricular 
mass), systolic function [left ventricular ejection fraction (LVEF)] 
and diastolic function [deceleration time of mitral inflow, the 
ratio of the peak mitral velocity of the early rapid filling wave 
(E) and mitral annulus early diastolic velocity (E’)], were stud-
ied using TTE including pulsed wave tissue Doppler imaging 
to record mitral annular velocity for myocardial velocity as 
previously recommended.16-19) LVEF was calculated by the 
modified Simpson’s method.16) 
Aortic root diameter at annulus, sinus of Valsalva (SOV), 
and sino-tubular junction, the end diastolic ascending aortic 
diameter, aortic valve thickness (at the mid portion of non-
coronary cusp) and mitral valve thickness (at the basal portion 
of anterior leaflet) were measured on the long axis view of 
2-dimensional based TEE images (Fig. 1).16) Mitral or aortic 
valve regurgitation was assessed and graded by widely accept-
ed criteria using color flow Doppler imaging.17) After mea-
surement of both diastolic and systolic diameters of descend-
ing thoracic aorta by M-mode, aortic stiffness and aortic 
elasticity indices were calculated as follows:20)21)
 · Aortic strain (%) = (systolic diameter of aorta - diastolic 
diameter of aorta) × 100/diastolic diameter
 · Aortic distensibility (cm2dyn-1 × 10-3) = 2 × aortic strain / 
(systolic BP - diastolic BP)
 · Aortic stiffness beta index = ln (systolic BP/diastolic BP) / 
[(systolic diameter of aorta - diastolic diameter of aorta) / dia-
stolic diameter]
All measurements were averaged over three cardiac cycles, 
and all subjects had 12-lead electrocardiography (ECG). One 
board certified cardiologist interpreted the ECG.
Statistical analysis
All descriptive measurements were expressed as mean ± 
SD. Differences between groups were compared using inde-
pendent samples t-test, or Chi-square test as appropriate. A 
subset analysis of patients was done by one-way ANOVA us-
ing the Tukey method as a post hoc test. Correlations between 
variables were determined by the Pearson correlation coeffi-
cient (r). To find the independent predictors of aortic valve 
thickening among clinical variables, logistic regression analy-
sis was done. Receiver operating characteristics (ROC) curve 
analysis was performed to assess the aortic valve thickness pre-
dicting AS. Statistical significance was considered with a p 
value of < 0.05. All tests were two-tailed. Statistical analysis 
was performed using the SPSS vs.13.0 software package (SPSS, 
Chicago, IL, USA). 
Results
Clinical characteristics
A total of 70 AS patients on treatment without clinical car-
Fig. 1. Transesophageal echocardiographic view of the aortic root 
showing how to measure the aortic root diameter at the annulus (label 
A), sinus of Valsalva (label B), and sino-tubular junction (label C), aortic 
valve thickness (white arrow head), and mitral valve thickness (white 
arrow).Journal of Cardiovascular Ultrasound 20 | March  2012
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diac symptoms were divided into group I (< 10 years, n = 50, 
mean age 26.7 ± 4.8 years) and group II (≥ 10 years, n = 20, 
mean age 33.9 ± 5.8 years) depending on their disease dura-
tion after first diagnosis (Table 1).
Except for the older age in AS group II than the control and 
AS group I, there were no significant differences in height, 
weight, body mass index, systolic and diastolic BP, pulse pres-
sure, heart rate, current smoker status and hypertension among 
the subjects. Five AS patients (5/70, 7%) had a history of hy-
pertension or were under treatment for it. No patient with AS 
had conduction disturbance, ischemic changes, and other sig-
nificant arrhythmias on 12-lead ECG. Also, no significant dif-
ferences in PR interval, QTc interval, and QRS duration were 
found in both the control and AS group.
Symptom duration (from the onset of symptoms to first di-
agnosis) and disease duration were longer in AS group II (14.0 
± 4.8 years, 2 to 25 years; 13.4 ± 3.0 years, 10 to 18 years, re-
spectively) than AS group I (4.2 ± 2.8 years, 0 to 12 years; 3.2 
± 2.2 years, 0 to 8 years, respectively) (p < 0.001, respective-
ly). Sixty-two (89%) (45/50, 90% in AS group I; 17/20, 85% 
in AS group II) of 70 AS patients were positive for human 
leukocyte antigen B27. AS group II had more elevated ESR 
and CRP, and higher prevalence of hip involvement and histo-
ry of etanercept use. There was no significant difference in 
BASDAI and history of uveitis and peripheral joint involve-
ment between the AS group I and AS group II. 
Echocardiographic characteristics 
Table 2 shows the echocardiographic data. Cardiac structure 
(left atrial size, left ventricular mass), LVEF, global function 
(Tei index), and diastolic function (deceleration time of mitral 
inflow, E/E’) did not show significant differences between the 
groups. Tissue Doppler imaging to record mitral annular ve-
locity for myocardial velocity revealed more decreased early 
diastolic (E’) and systolic (S’) velocities in AS group II compared 
to AS group I, and were also more decreased in AS group II 
than the control group for E’ velocity. There was no significant 
differences in E’ (11.8 ± 1.3 vs 11.0 ± 1.8, p = 0.061) and S’ 
Table 1. Clinical characteristics of the subjects enrolled in this study
Variables Control (n = 25) AS group I (n = 50) AS group II (n = 20)
Age, years   27.0 ± 2.5   26.7 ± 4.8      33.9 ± 5.8*,†
Height, cm 174.3 ± 5.1 173.7 ± 6.2 173.3 ± 6.0
Weight, kg   69.1 ± 9.8   68.4 ± 9.3     72.1 ± 12.1
Body surface area, m
2     1.8 ± 0.1     1.8 ± 0.1     1.8 ± 0.2
Body mass index, kg/m
2   22.7 ± 2.6   22.7 ± 2.8   24.0 ± 3.7
Systolic blood pressure, mmHg 127.1 ± 8.8    124.1 ± 10.9   128.6 ± 14.6
Diastolic blood pressure, mmHg   78.4 ± 6.2   76.0 ± 7.7   77.9 ± 8.2
Pulse pressure, mmHg   48.7 ± 7.4   48.5 ± 6.8     47.2 ± 10.1
Heart rate, beats/min     71.2 ± 12.0     70.1 ± 11.1   71.2 ± 9.6
Smoker, n (%)   5 (20) 13 (26) 7 (35)
Hypertension, n (%) 2 (8) 2 (4) 3 (15)
Electrocardiography
    PR interval, msec   156.2 ± 20.8   154.4 ± 19.8   155.3 ± 24.8
    QTc interval, msec   402.7 ± 16.1   401.7 ± 16.0   404.3 ± 19.8
    QRS duration, msec     95.4 ± 11.9     95.0 ± 12.5     97.3 ± 11.4
Rheumatologic features
    Symptom duration, yr NA     4.2 ± 2.8     14.0 ± 4.8†
    Disease duration, yr NA     3.2 ± 2.2    13.4 ± 3.0†
    HLA-B27, n (%) NA 45 (90) 17 (85)
    ESR, mm/h NA       9.1 ± 12.0      22.9 ± 23.3
‡
    CRP, mg/dL NA     0.6 ± 1.3      1.4 ± 1.7
‡
    Serum IgA, mg/dL NA   241.1 ± 84.9     285.7 ± 111.9
    BASDAI NA     2.5 ± 1.8     3.5 ± 2.0
    History of uveitis, n (%)  NA 12 (24)  5 (25)
    Peripheral joint involve, n (%) NA 20 (40)  9 (45)
    Hip involvement, n (%) NA 21 (42) 14 (70)
‡
    Etanercept use, n (%) NA   8 (16)   9 (45)
‡
Data are expressed as mean ± SD or percentages of numbers. *p < 0.01 vs. control, †p < 0.01 vs. AS group I, 
‡p < 0.05 AS group I. AS: ankylosing spondylitis, 
QTc: QT interval corrected for heart rate using Bazett formula, HLA B-27: Human leukocyte antigen B27, ESR: erythrocyte sedimentation rate, CRP: 
C-reactive protein, IgA: immunoglobulin A, BASDAI: the Bath Ankylosing Spondylitis Disease Activity Index, NA: not assessedCardiac Valve Disease in Ankylosing Spondylitis | So-Hee Park, et al.
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(8.6 ± 1.2 vs. 8.1 ± 1.2, p = 0.076) between the controls and 
the AS patients. 
Aortic root diameter at the annulus (20.4 ± 1.6 vs. 20.5 ± 1.4 
mm, p = 0.738), SOV (30.7 ± 2.7 vs. 31.0 ± 3.3 mm, p = 
0.708), and sino-tubular junction (24.2 ± 2.3 vs. 24.4 ± 2.1 
mm, p = 0.605) were not different significantly between the 
controls and AS group. AS group II showed an increased aortic 
root diameter at the SOV and at the sino-tubular junction com-
pared to AS group I. Ascending aortic diameter was more in-
creased in AS group II than in both AS group I and the controls.   
The thickness of both the aortic and mitral valve was more 
increased in both AS groups than in the controls. The preva-
lence of aortic and mitral regurgitation was not different be-
tween the controls and the patient groups (0% vs. 1.4% for 
aortic; 4% vs. 5.7% for mitral). ROC analysis showed that 
aortic valve thickness over 1.3 mm could predict AS with a 
sensitivity of 73%, specificity of 76%, and area under the 
curve of 0.8 (95% confidence interval, 0.707-0.887; p < 0.001) 
(Fig. 2). Aortic valve thickening was defined with this cut-off 
value > 1.3 mm. The prevalence of aortic valve thickening 
was higher in the AS groups (54/70, 77%) than in the con-
trols (9/25, 36%) (p < 0.001).
Aortic strain, aortic distensibility, and aortic stiffness beta 
index were more decreased in AS group II compared to other 
groups. There was no significant differences in aortic strain 
(13.1 ± 3.0% vs. 12.7 ± 4.1%, p = 0.602), aortic distensibili-
ty (0.6 ± 0.2 vs. 0.5 ± 0.2 cm2dyn-1 × 10-3, p = 0.589) and aor-
tic stiffness beta index (2.5 ± 0.3 vs. 2.6 ± 0.3, p = 0.357) be-
Table 2. Comparison of echocardiographic data between different subgroups
Variables Control (n = 25) AS group I (n = 50) AS group II (n = 20)
Cardiac structure and function
    LA size/BSA, mm/m
2 18.1 ± 1.7 18.2 ± 2.2 18.8 ± 2.4
    LV mass index, g/m
2 81.3 ± 5.8   81.6 ± 13.7 85.6 ± 9.3
    LVEF, % 61.7 ± 5.7 58.9 ± 5.2 60.0 ± 5.9
    LV Tei index   0.29 ± 0.06   0.30 ± 0.07   0.33 ± 0.06
    Deceleration time, ms 165.7 ± 23.9  175.0 ± 24.0 180.5 ± 16.2
    E’ 11.8 ± 1.3 11.5 ± 1.6       9.9 ± 1.8*,†
    S’   8.6 ± 1.2   8.3 ± 1.1    7.7 ± 1.3
‡
    E/E’   7.1 ± 1.3   7.1 ± 1.2   7.4 ± 1.6
Aortic root diameter, mm
    At the annulus 20.4 ± 1.6 20.4 ± 1.4 20.9 ± 1.4
    At the sinus of Valsalva 30.7 ± 2.7 30.4 ± 3.1  32.6 ± 3.2
§
    At the sino-tubular junction 24.2 ± 2.3 24.0 ± 2.0  25.5 ± 2.0
§
Ascending aortic diameter, mm 26.4 ± 2.3 27.2 ± 2.4     29.5 ± 2.8*,†
Aortic valve thickness, mm   1.2 ± 0.3     1.8 ± 0.7*     2.1 ± 0.8*
    Aortic valve thickening > 1.3 mm, n (%)   9 (36) 37 (74)*  17 (85)*
Mitral valve thickness, mm   0.9 ± 0.1     1.2 ± 0.3*     1.2 ± 0.4*
Aortic regurgitation, n (%) 0 (0) 1 (2) 0 (0)
Mitral regurgitation, n (%) 1 (4) 2 (4)   2 (10)
Aortic elasticity and stiffness
    Aortic strain, % 13.1 ± 3.0 13.8 ± 4.0       9.8 ± 2.7*,†
    Aortic distensibility, cm
2dyn
-1 × 10
-3   0.6 ± 0.2   0.6 ± 0.2       0.4 ± 0.1*,†
    Aortic stiffness beta index   2.5 ± 0.3   2.5 ± 0.3       2.8 ± 0.3*,†
*p < 0.01 vs. control, †p < 0.01 vs. AS group I, 
‡p < 0.05 vs. control, 
§p < 0.05 vs. AS group I. AS: ankylosing spondylitis, LA: left atrium, BSA: body surface 
area, LV: left ventricular, LVEF: left ventricular ejection fraction, E’: mitral annular early diastolic velocity, S’: mitral annular systolic velocity, E/E’: the ratio of 
the peak mitral velocity of the early rapid filling wave (E) and E’
Fig. 2. Receiver operating characteristics curve analysis showing aortic 
valve thickness over 1.3 mm predicts ankylosing spondylitis with a 
sensitivity of 73%, specificity of 76%, and area under the curve (AUC) 
of 0.8.
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tween the controls and both AS groups.
Aortic valve thickening and related clinical 
variables
On univariate analysis using Pearson correlation, no clinical 
variable was found to be related to mitral valve thickness. Aor-
tic valve thickness was significantly related to systolic BP (r = 
0.204, p = 0.047), disease duration (r = 0.329, p = 0.005), 
BASDAI (r = 0.342, p = 0.044), ESR (r = 0.483, p < 0.001), 
CRP (r = 0.495, p < 0.001), and Ig A (r = 0.292, p = 0.014). 
However, on both linear and binary logistic regression analy-
sis, an independent predictor for aortic valve thickening was 
not found among the clinical variables that had shown signifi-
cance on univariate analysis.   
Discussion
This study showed that both aortic and mitral valve thicken-
ing without regurgitation were noted in young male AS pa-
tients even without cardiac symptoms early in the course of 
their disease. To our knowledge, this is the largest study to eval-
uate the subclinical cardiac valve disease in early AS using TEE.
Comparison with previous echocardiographic 
studies
The cardiac abnormalities in AS may have been overesti-
mated in the past, compared with the results of our study. 
When examined by high resolution TEE, only aortic and mi-
tral valve thickening were noted as early changes in young AS 
patients, and the prevalence of aortic and mitral regurgitation 
was very low with no difference between the controls and pa-
tients (0% vs. 1.4% for aortic; 4% vs. 5.7% for mitral). Roldan 
et al.5) examined the aortic root and valve in 44 AS patients 
with a mean disease duration of 20 (± 11) years and in 40 pa-
tients by TEE. They found aortic root and valve disease in 
82% of AS patients compared to the controls (27%). These 
discrepancy between previous study and our data maybe in 
part explained by remarkable development in anti-inflamma-
tory therapy including anti-tumor necrosis factor therapy. 
Brunner et al.22) studied 100 male subjects with AS and a dis-
ease duration of more than 15 years using ECG and TTE. In 
patients with long-standing AS, there was no increased rate 
for valve regurgitation (mitral and aortic valve) and for ar-
rhythmia. We also found that the incidence of valve regurgita-
tion was not different from normal controls, and conduction 
abnormalities or arrhythmia was not discovered in AS patients 
if the disease duration was short (< 10 years). 
Changes of aortic root and ascending aorta
Aortic root diameter at the SOV and at the sino-tubular 
junction and ascending aortic diameter increased to a greater 
extent in the older AS patients than in the younger AS pa-
tients. Although young AS patients did not show significant 
differences in aortic elasticity index (aortic strain, aortic dis-
tensibility) and aortic stiffness (beta index) as compared to the 
controls, older AS patients (defined as group II in this study) 
had more decreased aortic elasticity and increased stiffness than 
the controls. A previous study to determine the aortic elasticity 
in 35 AS patients (younger than 40 years) using TTE at the 
ascending aorta found that aortic elasticity decreased in AS pa-
tients and this decrease was not related to the disease dura-
tion.23) Compared to this study, we used TEE with the advan-
tage of providing closer views of the aorta and aortic valve, 
and more detailed definition of thoracic aortic diameter than 
the TTE.8)9)24) The lack of sensitivity of TTE to detect cardiac 
abnormalities was also stressed in another study using TEE in 
29 male AS patients and 13 controls.8) 
Factors related to increased aortic diameter and decreased aor-
tic elasticity in older AS patients in our study may be complex 
because it has been known that there are many factors affecting 
aortic stiffness and aortic diameters including age, hypertension, 
obesity, and smoking.12)25) It was also reported that AS was asso-
ciated with subclinical atherosclerosis and arterial stiffness.26) 
However, our results did not show the association between CRP 
or ESR and valvular thickening. Recent studies have focused on 
vascular pathologies and showed impaired endothelial function, 
suggesting that atherosclerotic alterations could also be in-
volved in increased cardiovascular mortality.27)28) 
Ventricular function in ankylosing spondylitis
Myocardial failure due to left ventricular dysfunction may 
occur in AS patients.3)28-31) In our study it was noteworthy that 
we used tissue Doppler imaging, which can detect myocardial 
function with greater sensitivity,18)19) revealing no change in 
myocardial function in early AS patients. However, older AS 
patients showed depressed left ventricular function as identi-
fied by decreased myocardial velocities (E’ and S’) compared to 
the controls. Whether these differences were due to AS itself 
or to a higher prevalence of cardiovascular risk factors in older 
patients remains to be determined, and was beyond the scope 
of the present study. 
There are some limitations in this study. First, our study was 
conducted in a single center of Korea. Selection bias inherent to 
this may be unavoidable. In addition, because the subjects were 
not selected from a nation-wide registry, only small numbers 
were recruited, which could imply that these results may not be 
expandable to other populations. Second, no female AS patients 
agreed to the study, which meant we had to conduct the study 
only in male patients. Third, the design of our study was obser-
vational and not prospective. The evolution of early changes in 
aortic valve and root should be followed up in a larger long-
term prospective study. Fourth, we did not get any pathologic 
specimen which may provide information about the pathogene-
sis of valvular thickening in AS patients. 
Conclusion
Both aortic and mitral valve thickening without regurgita-Cardiac Valve Disease in Ankylosing Spondylitis | So-Hee Park, et al.
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tion were noted in male AS patients early in the course of 
their disease even without clinical cardiac manifestations. This 
subclinical change of the aorto-mitral valve in early AS should 
be considered and followed up to determine its prognostic im-
plication and evolution. 
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